 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12...2627282930313233343536...3738» |
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy: A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Jan 17, 2018
P1/2, N=21, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Oct 2017 --> Oct 2018
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Jan 12, 2018
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 12, 2018
P2, N=21, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| Talzenna (talazoparib) / Pfizer
New P3 trial, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Dec 29, 2017
P3, N=429, Recruiting, Sponsor: BioMarin Pharmaceutical
- | Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
New P2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Dec 29, 2017
P2, N=78, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment change, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Dec 22, 2017
P3, N=302, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2017 --> Dec 2018 N=2128 --> 302
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Enrollment change, Trial termination, Metastases: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) (clinicaltrials.gov) - Dec 20, 2017
P2, N=43, Terminated, Sponsor: German Breast Group
N=2128 --> 302 N=80 --> 43 | Active, not recruiting --> Terminated; very slow patient recruitment and concerns about the actuality of the study design
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: E-SPEC: Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=120, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
N=80 --> 43 | Active, not recruiting --> Terminated; very slow patient recruitment and concerns about the actuality of the study design Recruiting --> Active, not recruiting
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Dec 5, 2017
P2, N=58, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Enrollment open, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 4, 2017
P3, N=345, Recruiting, Sponsor: Synthon Biopharmaceuticals BV
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
New P1 trial, Surgery: Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - Dec 4, 2017
P1b, N=16, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- | Halaven (eribulin mesylate) / Eisai
Journal: Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer. (Pubmed Central) - Nov 16, 2017
In an in vivo xenograft model of TNBC, individual and combination treatments resulted in a decrease in both tumor volume and mitotic indices. Taken together, these studies highlight the potential of this novel drug combination, CYC065 and eribulin, to suppress the growth of TNBC cells in vitro and in vivo, warranting further clinical investigation.
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Enrollment change, Combination therapy, Metastases: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Nov 7, 2017
P1b/2, N=150, Recruiting, Sponsor: Eisai Inc.
Taken together, these studies highlight the potential of this novel drug combination, CYC065 and eribulin, to suppress the growth of TNBC cells in vitro and in vivo, warranting further clinical investigation. Active, not recruiting --> Recruiting | N=107 --> 150
- | Halaven (eribulin mesylate) / Eisai
New P2 trial: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) (clinicaltrials.gov) - Nov 6, 2017
P2, N=16, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Halaven (eribulin mesylate) / Eisai
Review, Journal: Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma? (Pubmed Central) - Oct 28, 2017
Also, to be further investigated is the use of trabectedin in sarcoma subtypes which were excluded from the phase III study, but in which activity has been documented in earlier trials and subsequent reports. Combinations of trabectedin with other agents, particularly doxorubicin, have been explored, but the data to date do not support the routine use of these regimens.
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy: Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Oct 27, 2017
P1, N=18, Recruiting, Sponsor: Tom Badgett
Combinations of trabectedin with other agents, particularly doxorubicin, have been explored, but the data to date do not support the routine use of these regimens. Trial primary completion date: Jun 2017 --> Jun 2019
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2017 --> Jun 2019 Trial primary completion date: Aug 2007 --> Dec 2017
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer (clinicaltrials.gov) - Oct 25, 2017
P2, N=60, Recruiting, Sponsor: University of Washington
Trial primary completion date: Aug 2007 --> Dec 2017 Trial primary completion date: Feb 2018 --> Aug 2018
- |||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment open, Trial initiation date, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Oct 20, 2017
P3, N=328, Recruiting, Sponsor: Immunomedics, Inc.
Trial primary completion date: Feb 2018 --> Aug 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Oct 2017
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Oct 19, 2017
P1, N=37, Active, not recruiting, Sponsor: Corcept Therapeutics
Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Oct 2017 Trial primary completion date: Sep 2017 --> Dec 2017
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Oct 16, 2017
P2, N=118, Active, not recruiting, Sponsor: Asan Medical Center
Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Sep 2018 --> Sep 2019
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Oct 16, 2017
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2018 --> Sep 2019 Trial primary completion date: Dec 2017 --> Aug 2007
- | veliparib (ABT-888) / AbbVie, Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial withdrawal, BRCA Biomarker, Metastases: Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients (clinicaltrials.gov) - Oct 10, 2017
P2, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center at San Antonio
Trial primary completion date: Dec 2017 --> Aug 2007 N=30 --> 0 | Not yet recruiting --> Withdrawn
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Oct 9, 2017
P1, N=45, Recruiting, Sponsor: City of Hope Medical Center
N=30 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2017 --> Dec 2018
- Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial termination, Metastases: Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer (clinicaltrials.gov) - Oct 5, 2017
P=N/A, N=23, Terminated, Sponsor: Centre Oscar Lambret
Trial primary completion date: Dec 2017 --> Dec 2018 N=38 --> 23 | Recruiting --> Terminated; Lack of enrollment
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy, Metastases: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Oct 3, 2017
P1b/2, N=107, Active, not recruiting, Sponsor: Eisai Inc.
N=38 --> 23 | Recruiting --> Terminated; Lack of enrollment Trial primary completion date: Oct 2017 --> Nov 2018
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) (clinicaltrials.gov) - Sep 25, 2017
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Oct 2017 --> Nov 2018 Trial primary completion date: Aug 2018 --> Dec 2018
- |||||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy: EMERALD: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (clinicaltrials.gov) - Sep 18, 2017
P3, N=480, Recruiting, Sponsor: Japan Breast Cancer Research Group
Trial primary completion date: Aug 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- ||||| Talzenna (talazoparib) / Pfizer
Enrollment closed, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Sep 12, 2017
P3, N=442, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy: EMERALD: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (clinicaltrials.gov) - Aug 29, 2017
P3, N=480, Not yet recruiting, Sponsor: Japan Breast Cancer Research Group
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Trial primary completion date, Combination therapy, Metastases: Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer (clinicaltrials.gov) - Aug 28, 2017
P1/2, N=92, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> May 2015
- |||||||||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
New P3 trial, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 24, 2017
P3, N=345, Not yet recruiting, Sponsor: Synthon Biopharmaceuticals BV
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal: Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. (Pubmed Central) - Aug 24, 2017
P3
Conclusions Among patients with HER2-negative metastatic breast cancer and a germline BRCA mutation, olaparib monotherapy provided a significant benefit over standard therapy; median progression-free survival was 2.8 months longer and the risk of disease progression or death was 42% lower with olaparib monotherapy than with standard therapy. (Funded by AstraZeneca; OlympiAD ClinicalTrials.gov number, NCT02000622 .).
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, PD(L)-1 Biomarker, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Aug 17, 2017
P2, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
(Funded by AstraZeneca; OlympiAD ClinicalTrials.gov number, NCT02000622 .). Not yet recruiting --> Recruiting
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy, Metastases: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Aug 16, 2017
P1b/2, N=107, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Oct 2017
- | Biomarker, Review, Journal: Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. (Pubmed Central) - Aug 11, 2017
Further progress in STS management will rely on novel trial design, subtype-specific therapies and validation of biomarkers to tailor therapy. Immunotherapy has shown promise as a new, but yet undiscovered frontier in the management of STS.
- ||| Halaven (eribulin mesylate) / Eisai
New trial, Retrospective data, Metastases: Halaven Patient Registry (Metastatic Breast Cancer, MBC) (clinicaltrials.gov) - Aug 10, 2017
P=N/A, N=500, Recruiting, Sponsor: Chang Gung Memorial Hospital
- ||||| Halaven (eribulin mesylate) / Eisai
New P1/2 trial, Combination therapy: Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors (clinicaltrials.gov) - Aug 9, 2017
P1/2, N=86, Recruiting, Sponsor: Eisai Inc.
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Aug 9, 2017
P=N/A, N=8, Active, not recruiting, Sponsor: City of Hope Medical Center
Immunotherapy has shown promise as a new, but yet undiscovered frontier in the management of STS. Recruiting --> Active, not recruiting
- ||| Halaven (eribulin mesylate) / Eisai, Turalio (pexidartinib) / Daiichi Sankyo
Enrollment closed, Trial primary completion date, Metastases: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Aug 8, 2017
P1/2, N=68, Active, not recruiting, Sponsor: Hope Rugo, MD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Feb 2017
- | Lartruvo (olaratumab) / Eli Lilly
Review, Journal: Olaratumab for the treatment of soft tissue sarcoma. (Pubmed Central) - Aug 5, 2017
Despite recent advances in treatment beyond first line - with the FDA approval of pazopanib, eribulin and trabectidin - overall survival for patients with metastatic disease remains in the region of 12-19 months...Ongoing trials are underway to further demonstrate the mechanism of action. This review will document the studies involved in the development of olaratumab in the treatment of soft tissue sarcomas.
- |||||| Talzenna (talazoparib) / Pfizer
Enrollment open, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Aug 1, 2017
P3, N=429, Recruiting, Sponsor: Pfizer
This review will document the studies involved in the development of olaratumab in the treatment of soft tissue sarcomas. Active, not recruiting --> Recruiting
- | Biomarker, Journal: Emerging Treatment using Tubulin Inhibitors in Advanced Non-Small Cell Lung Cancer. (Pubmed Central) - Jul 26, 2017
The article then provides a summary of novel tubulin inhibitors, including cabazitaxel, eribulin, ixabepilone, patupilone, plinabulin, new colchicine analogues and others...Expert Opinion: Tubulin inhibitors will likely continue to play important roles in NSCLC management due to the advent of novel agents and combinations. Through further understanding of tumor biology, investigation of drug resistance, and development of predictive biomarkers, we will be better positioned to incorporate microtubule inhibition into patient specific treatment strategies.
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Jul 25, 2017
P1, N=37, Active, not recruiting, Sponsor: Corcept Therapeutics
Through further understanding of tumor biology, investigation of drug resistance, and development of predictive biomarkers, we will be better positioned to incorporate microtubule inhibition into patient specific treatment strategies. Trial primary completion date: Mar 2017 --> Sep 2017
- | Cyramza (ramucirumab) / Eli Lilly, Halaven (eribulin mesylate) / Eisai
Journal: Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. (Pubmed Central) - Jul 19, 2017
Trial primary completion date: Mar 2017 --> Sep 2017 Ramucirumab combined with eribulin did not significantly improve PFS in advanced MBC.
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: KELLY: Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (clinicaltrials.gov) - Jul 19, 2017
P2, N=44, Not yet recruiting, Sponsor: MedSIR
- | Trial primary completion date, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Jul 6, 2017
P2, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
Ramucirumab combined with eribulin did not significantly improve PFS in advanced MBC. Trial primary completion date: Jun 2017 --> Jun 2018
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 2, 2017
P2, N=58, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: May 2017 --> Oct 2017
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
New P2 trial, PD(L)-1 Biomarker, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Jun 27, 2017
P2, N=33, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: HAL03T: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 27, 2017
P=N/A, N=160, Recruiting, Sponsor: Eisai Co., Ltd.
Trial primary completion date: May 2017 --> Oct 2017 Trial primary completion date: Jun 2017 --> Nov 2018